EUS-Guided Choledocho-duodenostomy Using Lumen Apposing Stent Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Trial (DRA-MBO Trial)

医学 四分位间距 内镜逆行胰胆管造影术 随机对照试验 支架 不利影响 外科 内科学 胰腺炎
作者
Anthony Yuen Bun Teoh,Betrand Napoleon,Rastislav Kunda,Paolo Giorgio Arcidiacono,Pradermchai Kongkam,Alberto Larghi,Van der Merwe,Jeremies Jacques,Romain Legros,Ratanachu-Ek Thawee,Payal Saxena,Maridi Maridi,Lívia Archibugi,Shannon M. Chan,Fabien Fumex,Arthur J. Kaffes,Mark Tsz Wah,Nouredin Messaoudi,Gianenrico Rizzatti,Kelvin K. Ng,Enders K. Ng,Philip Wai Yan Chiu
出处
期刊:Gastroenterology [Elsevier]
卷期号:165 (2): 473-482.e2 被引量:46
标识
DOI:10.1053/j.gastro.2023.04.016
摘要

Background & AimsSeveral studies have compared primary endoscopic ultrasound (EUS)-guided biliary drainage to endoscopic retrograde cholangiopancreatography (ERCP) with insertion of metal stents in unresectable malignant distal biliary obstruction (MDBO) and the results were conflicting. The aim of the current study was to compare the outcomes of the procedures in a large-scale study.MethodsThis was a multicenter international randomized controlled study. Consecutive patients admitted for obstructive jaundice due to unresectable MDBO were recruited. Patients were randomly allocated to receive EUS-guided choledocho-duodenostomy (ECDS) or ERCP for drainage. The primary outcome was the 1-year stent patency rate. Other outcomes included technical success, clinical success, adverse events, time to stent dysfunction, reintervention rates, and overall survival.ResultsBetween January 2017 and February 2021, 155 patients were recruited (ECDS 79, ERCP 76). There were no significant differences in 1-year stent patency rates (ECDS 91.1% vs ERCP 88.1%, P = .52). The ECDS group had significantly higher technical success (ECDS 96.2% vs ERCP 76.3%, P < .001), whereas clinical success was similar (ECDS 93.7% vs ERCP 90.8%, P = .559). The median (interquartile range) procedural time was significantly shorter in the ECDS group (ECDS 10 [5.75–18] vs ERCP 25 [14–40] minutes, P < .001). The rate of 30-day adverse events (P = 1) and 30-day mortality (P = .53) were similar.ConclusionBoth procedures could be options for primary biliary drainage in unresectable MDBO. ECDS was associated with higher technical success and shorter procedural time then ERCP. Primary ECDS may be preferred when difficult ERCPs are anticipated. This study was registered to Clinicaltrials.gov NCT03000855. Several studies have compared primary endoscopic ultrasound (EUS)-guided biliary drainage to endoscopic retrograde cholangiopancreatography (ERCP) with insertion of metal stents in unresectable malignant distal biliary obstruction (MDBO) and the results were conflicting. The aim of the current study was to compare the outcomes of the procedures in a large-scale study. This was a multicenter international randomized controlled study. Consecutive patients admitted for obstructive jaundice due to unresectable MDBO were recruited. Patients were randomly allocated to receive EUS-guided choledocho-duodenostomy (ECDS) or ERCP for drainage. The primary outcome was the 1-year stent patency rate. Other outcomes included technical success, clinical success, adverse events, time to stent dysfunction, reintervention rates, and overall survival. Between January 2017 and February 2021, 155 patients were recruited (ECDS 79, ERCP 76). There were no significant differences in 1-year stent patency rates (ECDS 91.1% vs ERCP 88.1%, P = .52). The ECDS group had significantly higher technical success (ECDS 96.2% vs ERCP 76.3%, P < .001), whereas clinical success was similar (ECDS 93.7% vs ERCP 90.8%, P = .559). The median (interquartile range) procedural time was significantly shorter in the ECDS group (ECDS 10 [5.75–18] vs ERCP 25 [14–40] minutes, P < .001). The rate of 30-day adverse events (P = 1) and 30-day mortality (P = .53) were similar. Both procedures could be options for primary biliary drainage in unresectable MDBO. ECDS was associated with higher technical success and shorter procedural time then ERCP. Primary ECDS may be preferred when difficult ERCPs are anticipated. This study was registered to Clinicaltrials.gov NCT03000855.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
那种发布了新的文献求助10
刚刚
李健的小迷弟应助娜行采纳,获得10
刚刚
高高迎蓉关注了科研通微信公众号
刚刚
专注的水壶完成签到 ,获得积分10
刚刚
1秒前
1秒前
1秒前
Ava应助doudou采纳,获得10
2秒前
2秒前
上官若男应助可颂采纳,获得10
2秒前
3秒前
哎呀妈呀发布了新的文献求助10
3秒前
3秒前
zzx完成签到,获得积分10
4秒前
何何完成签到 ,获得积分10
4秒前
jackhlj完成签到,获得积分10
4秒前
香蕉觅云应助乐小佳采纳,获得10
5秒前
大胆夜绿完成签到,获得积分10
5秒前
青wu完成签到,获得积分10
5秒前
6秒前
竹筏过海应助锦鲤云间月采纳,获得30
6秒前
菠萝吹雪遇见梨花诗完成签到 ,获得积分10
6秒前
杨天水发布了新的文献求助10
7秒前
7秒前
VDC应助梁liang采纳,获得30
7秒前
chen发布了新的文献求助10
7秒前
7秒前
青wu发布了新的文献求助10
8秒前
a龙完成签到,获得积分10
8秒前
眯眯眼的老鼠完成签到,获得积分20
8秒前
无花果应助科研通管家采纳,获得10
8秒前
斯文败类应助科研通管家采纳,获得10
9秒前
wanci应助嗯哼采纳,获得10
9秒前
nanan完成签到,获得积分10
9秒前
9秒前
星辰大海应助科研通管家采纳,获得10
9秒前
Hungrylunch应助科研通管家采纳,获得20
9秒前
Cassie应助科研通管家采纳,获得10
9秒前
爆米花应助科研通管家采纳,获得10
9秒前
酷波er应助科研通管家采纳,获得10
9秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527304
求助须知:如何正确求助?哪些是违规求助? 3107454
关于积分的说明 9285518
捐赠科研通 2805269
什么是DOI,文献DOI怎么找? 1539827
邀请新用户注册赠送积分活动 716708
科研通“疑难数据库(出版商)”最低求助积分说明 709672